SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Emerging Challenges in Primary Care 2017 Birmingham, AL
Activity/Course #:
: 05.20.17PC

Cost:
: Free
Release/Start Date:
: May 20 2017
Expiration Date:
: May 20 2017
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Live EC Primary Care
Estimated Time To Complete CME Activity:
: 7.0 hours
Credit(s):
: 7.0 AMA PRA Category I Credit(s)
7.0 AANP Contact hour(s) which includes 2.75 pharmacology hour(s)
Hardware/Software Requirements:

Saturday, May 20, 2017

The Sheraton Birmingham Hotel
2101 Richard Arrington Junior Boulevard North
Birmingham, AL 35203
(205) 324-5000

Registration Fee
There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking

A self-parking rate of $8.00 is available at the hotel - Lot 7.

Hotel Guest Rooms

NACE has reserved a sleeping room rate of $139 per night at the Sheraton Birmingham Hotel. To reserve your room at this rate, call reservations at (205) 324-5000 using group code National Association for Continuing Education by April 28, 2017.

Program Summary

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives
At the conclusion of this program, participants should be able to:

  1. Describe the role of the kidney in glucose metabolism in health and disease; Review the physiologic effects and clinical efficacy of SGLT-2 therapy in various patient populations; Review emerging data on possible renal and macrovascular effects of evidence-based diabetes treatment options; Integrate the impact of treatment decisions on postprandial hyperglycemia and risk of hypoglycemia.

  2. Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications; Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability; Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control; Discuss various GLP-1 RA combination strategies with or as a possible alternative to basal insulin in the diabetic patient not at glycemic target.

  3. Describe the typical clinical presentation of a patient with possible idiopathic pulmonary fibrosis (IPF); Discuss the diagnostic approach to a patient with suspected IPF; Discuss and contrast the available pharmacotherapeutic options for patients with IPF; Discuss and contrast the available nonpharmacotherapeutic options for patients with IPF.

  4. Understand the pathophysiology of Obstructive Sleep Apnea; Recognize the clinical features and presentation of Sleep Apnea; Describe comorbidities associated with Sleep Apnea; Perform an appropriate evaluation to accurately diagnose Sleep Apnea; Discuss recent advances in management of Obstructive Sleep Apnea. 

  5. List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease; Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction; Discuss ACC guidelines on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease; Employ guideline-directed treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.
  6. Recognize that Obesity is a disease frequently associated with expansion of the perivascular adipose tissue which is associated with increased production of atherogenic adipokines and other biologically active molecules; Understand the central role of abdominal and perivascular adipose tissue as a root cause of co-morbidities and cardiometabolic risk; Understand that excess amounts of visceral and perivascular adipocytes are associated with an impairment of insulin sensitivity and other co-morbities; Recognize that Obesity itself, even without associated co-morbidities of hyperglycemia, hypertension and hyperlipidemia are responsible for cardiovascular disease risk.

 
Agenda*

7:30-8:00

  Continental Breakfast and Registration
8:00-8:10   Welcome Remarks
Jack Kravitz, MD
8:10-9:20  

Integrating Data on Macrovascular and Microvascular Outcomes into Diabetes Management: Evolving Treatment Strategies
Robert Busch, MD, FACE

9:20-10:30   GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
Robert Busch, MD, FACE
10:30-10:50   Break
10:50-12:00   Idiopathic Pulmonary Fibrosis: Defining the Role of the Primary Care Clinician in Diagnosis and Therapy
Arunabh Talwar, MD, FCCP
12:00-1:10  

Lunch (on your own)

1:10-2:20   Recent Advances in Management of Obstructive Sleep Apnea
Arunabh Talwar, MD, FCCP
2:20-3:30  

New Agents, New Options, and Expanded Potential In Lipid Management: Integrating The Data Into Practice
Mahfouz El Shahawy, MD, MS, FACP

 3:30-3:45 

Break

   3:45-4:55 

Obesity, Even Without Comorbidities, Is a Disease
Mahfouz El Shahawy, MD, MS, FACP

 4:55-5:00 

Program Summary and Closing Remarks
Jack Kravitz, MD

 
*Agenda subject to change.
 
Faculty
Robert S. Busch, MD, FACE
Director of Clinical Research
Albany Medical Faculty: Community Endocrine Group
Albany, NY

Mahfouz El Shahawy, MD, MS, FACP
Clinical Professor of Medicine
Universities of Florida and South Florida
Medical Director
Cardiovascular Health Assessment Center
President, Cardiovascular Center of Sarasota
Sarasota, FL

Arunabh Talwar, MD, FCCP
Director, Pulmonary Hypertension and Advanced Lung Disease Program
North Shore University Hospital, Manhasset, New York
Professor Of Medicine
Hofstra Northwell School of Medicine
Hofstra University
Hempstead, NY

Planning Committee

Gregg Sherman, MD
Course Director
National Association for Continuing Education

Plantation, FL

Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Cassandra A. McCullough, MBA

Chief Executive Officer

Association of Black Cardiologists

New York, NY

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education

Plantation, FL

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7 contact hours of continuing education (which includes 2.75 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
Emerging Challenges in Primary Care: 2017 is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.; an educational grant from Sanofi US and Regeneron Pharmaceuticals; and an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.